The disease is associated with a peptide called CGRP (calcitonin gene-related peptide), which is known to convey pain signals to the brain. The author’s theory identifies baroreceptors, specialized cells involved in blood pressure regulation, as the key players in migraine pathology.

Baroreceptors are located near the heart and monitor changes in blood pressure, activating the sympathetic or parasympathetic nervous system as needed. In migraine, the sympathetic nervous system becomes hyperactive, leading to desensitization. This desensitization impairs the body’s ability to increase blood pressure and recruit energy to cells, leaving baroreceptors and vascular smooth muscle cells with insufficient energy to function properly.

When cells experience low energy levels, they enter a state of stress and begin secreting CGRP. While CGRP is well-known for transmitting pain signals to the brain, the author argues that its primary role is to recalibrate the baroreceptors’ activation range to accommodate the stress. However, this compensatory mechanism fails when energy levels remain critically low, leading to persistent stress and migraine pain.

Triggers for this process include prolonged fasting, sleep deprivation, alcohol consumption, and fluctuations in temperature or air pressure, all of which activate the sympathetic nervous system. Overactivation eventually leads to desensitization, compounding the problem and triggering migraines. The theory aligns with existing research that links CGRP to migraine but introduces the novel perspective of baroreceptor involvement.

While CGRP inhibitors have been developed and approved for migraine treatment, their efficacy is limited as they primarily address pain rather than the underlying cause. The author proposes an alternative approach: using beta blockers to prevent sympathetic nervous system desensitization. Beta blockers reduce the system’s workload, lowering the risk of desensitization and providing a preventative strategy against migraine attacks.

Interestingly, this recommendation aligns with decades-old clinical practices, as beta blockers have long been used to prevent migraines. The theory provides a biological explanation for why this approach works and emphasizes the importance of avoiding triggers to maintain energy balance in baroreceptor cells.

In conclusion, the author’s theory offers a fresh perspective on migraine by identifying baroreceptors as central to the disease mechanism. It integrates existing knowledge about CGRP and the sympathetic nervous system while highlighting a biological cause for migraines. Although the treatment recommendations do not drastically depart from current practices, the theory deepens our understanding of migraine pathology.